# Arctic Vision (Shanghai) Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arctic-vision-shanghai-biotechnology-co

- Industry: Healthcare Specialists
- Headquarters: Shanghai, China
- Website: www.arcticvision.com
- Total disclosed funding: $132M
- Latest round: Series B (Mar 9, 2021)
- Investors on record: 6

## About

Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a China-based company specializing in the development of innovative ophthalmic therapies to address unmet clinical needs in eye care.Founded in 2019 and headquartered in Shanghai, China, Arctic Vision focuses on creating advanced treatments for various eye conditions. The company has successfully completed three funding rounds, with the latest being a Series B round in March 2021, raising a total of USD 100 mn led by Loyal Valley Capital, alongside other investors such as Tencent Investment. The CEO, Dr. Eddy Wu, continues to lead the firm, leveraging his experience to drive its growth.Arctic Vision specializes in developing innovative ophthalmic therapies that address significant unmet clinical needs. The company’s core product offerings encompass a portfolio that spans from pre-clinical to commercial stages, focusing on advanced treatment options for various eye conditions, including glaucoma, retinal diseases, and dry eye syndromes. These products aim to improve patient outcomes through novel mechanisms of action, such as targeted drug delivery and enhanced therapeutic efficacy, primarily serving ophthalmic healthcare providers and their patients across China, Asia, and other potential global markets.Arctic Vision's revenue generation model is centered around B2B transactions, supplying pharmaceutical products to healthcare institutions and specialty pharmacies. The company collaborates with distributors and healthcare providers to ensure product availability in clinics and hospitals, with structured pricing based on volume purchases or exclusive distribution rights in specific regions. The flagship products cater to a broad range of ophthalmic treatments, optimizing accessibility and value for healthcare providers and patients.In March 2021, Arctic Vision (Shanghai) Biotechnology Co., Ltd. raised USD 100 mn in Series B funding led by Loyal Valley Capital. This funding will be utilized to accelerate portfolio expansion, clinical development, and commercialization. The company plans to introduce new products targeting various eye conditions and is focusing on expanding into new markets across Asia and potentially beyond by 2023. The strategic investments aim to enhance their operational capabilities and market reach.

## Funding rounds

- Series B, Mar 9, 2021, $100M — 5Y Capital, Tencent Investment, Loyal Valley Capital, Pivotal Life Sciences, Nan Fung Life Sciences, Octagon Capital Investments
- Series A, Jul 14, 2020, $32M — 5Y Capital, Pivotal Life Sciences, Nan Fung Life Sciences
- Seed, Oct 1, 2019 — Pivotal Life Sciences, Nan Fung Life Sciences

## Investors

- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Seed, Series A, Series B
- Nan Fung Life Sciences — Seed, Series A, Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B
- Tencent Investment — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series B
- Octagon Capital Investments (https://capitalatlas.ai/funds/octagon-capital-investments) — Series B